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INTRODUCTION
Bronchial asthma is characterized by airway hyperresponsive-
ness, eosinophilic airway inflammation and increased immu-
noglobulin E (IgE) levels. These effects are mediated mainly by 
type 2 helper (Th2) cells.
1-3 In particular, eotaxin, RANTES, inter-
leukin (IL)-4, IL-5 and IL-13, which are produced by Th2 cells, 
are all related to airway hyperresponsiveness and inflammato-
ry changes in the airway through the activation of eosinophils 
and IgE production by B cells.
4-6 Because the influx and differ-
entiation of Th2 cells are important factors in the development 
and aggravation of asthma, increasing interest has been focused 
on investigations that target the activation of Th2 cells or the 
modulation of the Th1/Th2 balance to prevent and treat asthma.
Human immune reactions to external antigens are composed 
of innate and acquired responses. Innate immunity plays a par-
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ticularly crucial role in primary defense against external patho-
gens and signaling for the induction of acquired immunity.
7,8 
Allergic diseases are caused by the abnormal modulation of ac-
quired immunity, which is especially affected by the activation 
of Th2 cells.
9 Recent studies, however, have demonstrated that 
factors related to innate immunity are involved in early allergic 
reactions
10 and that either a Th2 immune response alone or a 
combination of Th1 and Th2 immune responses is involved in 
cases in which allergic diseases do not develop.
11 In addition, in 
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Purpose:  Lactobacilli are probiotic bacteria that are effective in the management of allergic diseases or gastroenteritis. It is hypothesized that such 
probiotics have immunoregulatory properties and promote mucosal tolerance. Our goal was to investigate whether Lactobacillus casei rhamnosus 
Lcr35 could inhibit airway inflammation in an ovalbumin (OVA)-induced murine model of asthma.  Methods:  BALB/c mice aged 6 weeks were used 
in the present study. Lactobacillus casei rhamnosus Lcr35 was administered daily, starting 1 week prior to the first OVA sensitization (group 1) and 2 
days before the first 1% OVA airway challenge (group 2). Mice that received only saline at both sensitization and airway challenge time points were 
used as negative controls (group 3), and those that had OVA-induced asthma were used as positive controls (group 4). Airway responsiveness to 
methacholine was assessed, and bronchoalveolar lavage (BAL) was performed. At the endpoint of the study, total IgE as well as OVA-specific IgE, 
IgG1 and IgG2a in serum was measured by enzyme-linked immunosorbent assay. Lung pathology was also evaluated.  Results:  Airway hyperrespon-
siveness, total cell counts and the proportion of eosinophils in BAL fluid were significantly decreased in group 1 compared with group 4 (P<0.05). To-
tal serum IgE levels were also significantly decreased in group 1 compared with group 4. Serum levels of OVA-specific IgE, IgG1 and IgG2a were not 
significantly influenced by treatment with Lcr35. There was significantly less peribronchial and perivascular infiltration of inflammatory cells in group 
1 compared with group 4; however, there were no significant differences in methacholine challenge, BAL, serology or histology between groups 2 
and 4.  Conclusions:  Oral treatment with Lcr35 prior to sensitization can attenuate airway inflammation and hyperreactivity in a mouse model of 
allergic airway inflammation. These results suggest that Lcr35 may have potential for preventing asthma.
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animal models of allergic diseases, allergen-specific Th1 cells 
fail to counterbalance Th2 cell-induced airway hyperrespon-
siveness.
12 These results imply that other mechanisms may be 
involved in the pathogenesis of allergic diseases through the 
Th1/Th2 imbalance. Numerous investigators have focused on 
the activation of regulatory T cells or the induction of immuno-
logic tolerance as factors in the development of allergies.
13 Im-
munologic tolerance induced by oral administration of aller-
gens is effective in the treatment of allergic diseases and has 
less risk of adverse reactions compared with other administra-
tion methods.
14,15
Many studies based on the hygiene hypothesis have indicated 
that alterations in intestinal flora can prevent and treat aller-
gies.
14,15 Attention has been given to the use of intestinal flora as 
probiotics.
16-18 Probiotics are usually defined as live microbial 
food ingredients beneficial to health. These ingredients com-
prise normal commensal bacteria that are part of the healthy 
human gut microflora. Bifidobacteria and lactobacilli are rep-
resentative probiotics. Allergic diseases can be prevented with 
treatment of intestinal flora with probiotics,
15,16 and probiotics 
can prevent and treat allergic diseases.
17-19 In a murine model of 
asthma, administration of Lactobacillus reuteri and Lactobacil-
lus rhamnosus GG decreased airway hyperresponsiveness, the 
number of inflammatory cells in bronchoalveolar lavage (BAL) 
fluid, and inflammation of lung tissue.
20,21
This study was conducted to investigate the effects of L. rham-
nosus, a probiotic, on the prevention of asthma using a murine 
model of asthma.
MATERIALS AND METHODS
Establishment of a murine model of asthma
A murine model of asthma was established according to a 
modification of the methods proposed by Steinmetz et al.
22 
Briefly, female BALB/c mice aged 6 weeks were sensitized by 
intraperitoneal administration of a mixture of ovalbumin (OVA; 
10 µg; grade V, Sigma Inc., St. Louis, MO, USA) and alum (2.25 
mg; Imject
®, Pierce, Rockford, IL, USA). One week after the first 
sensitization, the mixture was administered intraperitoneally a 
second time. Seven days later, the mice inhaled 1% OVA using 
an ultrasonic sprayer (Nescosonic UN-511, Alfresa, Osaka, Ja-
pan) every day for 3 days (Fig. 1). The mice were divided into 
four groups of seven mice each: those that received Lactobacil-
lus casei rhamnosus Lcr35 from 1 week before the primary sen-
sitization to the endpoint of the study (group 1), those that re-
ceived Lactobacillus casei rhamnosus Lcr35 from 2 days before 
inhalation of 1% OVA to the endpoint of the study (group 2), 
those that received only saline (instead of OVA) at both sensiti-
zation and airway challenge (group 3, negative controls), and 
those in which asthma was induced (group 4, positive controls). 
Lactobacillus casei rhamnosus Lcr35 was administered orally at 
a CFU of 1×10
9 per day (Fig. 1).
20
Measurement of airway hyperresponsiveness
The mice inhaled normal saline and methacholine aerosol (5, 
10, 25 and 50 mg/mL), and a pulmonary function test was per-
formed using an animal airway resistance recorder (body vol-
ume change recorder, All Medicus, Seoul, Korea) 24 hours after 
inhalation of 1% OVA. Enhanced pause (Penh) was measured at 
10-s intervals for 3 minutes after inhalation of saline and each 
concentration of methacholine.
BAL and cell fractionation
After measurement of airway hyperresponsiveness, the tra-
chea was immediately exposed after anesthesia by intraperito-
neal administration of ketamine-xylazine. BAL was performed 
through a catheter inserted into the exposed trachea following 
instillation of normal saline (2 mL) at 37°C. The BAL fluid was 
centrifuged at 1,500 rpm for 2 minutes at 4°C. After discarding 
the supernatant, we washed the resultant pellet with PBS and 
resuspended it in 100 μL PBS. Total BAL cell counts were per-
formed using a haemacytometer. A differential cell count was 
performed using Diff-Quik staining on the basis of morpholog-
ic criteria and using a light microscope to evaluate at least 200 
cells per slide.
Measurement of serum immunoglobulin
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Fig. 1.  Experimental protocol for the induction of allergic asthma and treatment 
scheme. Four groups of female BALB/c mice were analyzed. Lactobacillus rham-
nosus (Lcr35)-treated groups (group 1 and group 2) were sensitized to OVA with 
adjuvant via intraperitoneal injections, while the control groups (group 3 and 
group 4) were sensitized with equivalent amounts of saline and OVA, respec-
tively. Group 1: Lactobacillus rhamnosus (Lcr35)-treated group starting 7-day 
before first OVA sensitization, Group 2: Lactobacillus rhamnosus (Lcr35)-treated 
group starting 2-day before first 1% OVA challenge, Group 3: saline-sensitized 
and -challenged group, Group 4: OVA-sensitized and -challenged group.Preventive Effect of Probiotics in Asthma
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serum was separated from the blood clot by centrifugation at 
2,500 rpm for 20 minutes at 4°C. Absorbance of OVA-specific 
IgE, IgG1 and IgG2a, as well as total IgE, was measured using en-
zyme-linked immunosorbent assay.
Histological examination of murine lung tissue
After BAL, the murine lung was resected, fixed with 10% for-
malin, and embedded in paraffin. Specimens were cut into 4 
μm sections. The microsections were stained with hematoxylin-
eosin and examined under a magnification of ×100.
Statistical analysis
Groups were compared using the Mann-Whitney U test. All 
statistical analyses were performed using SPSS software version 




The mean Penh value at 50 mg/mL methacholine was 4.87±0.82 
in group 1, 6.13±0.97 in group 2, 2.88±0.38 in group 3, and 7.70± 
1.21 in group 4. The mean Penh value decreased by 37% in group 
1 compared with group 4 (P<0.05; Fig. 2).
BAL and cell fractionation
The mean total number of cells (×10
5/mL) in the BAL fluid was 
3.96±0.46 in group 1, 6.08±0.77 in group 2, 2.37±0.24 in group 3, 
and 6.21±0.65 in group 4. As with airway hyperresponsiveness, 
the total number of cells in the BAL fluid was significantly less 
in group 1 compared with group 4 (P<0.05; Fig. 3). The mean 
percentage of eosinophils in the BAL fluid was 6.19±1.88% in 
group 1 and 13.88±2.06% in group 4 (P<0.05; Fig. 4). There were 
no significant differences in the percentage of eosinophils be-
tween groups 2 and 4 (Fig. 4).
Serum levels of total IgE and OVA-specific IgE
Mean total IgE levels (A450nm) were 1.77±0.13 in group 1 and 
2.48±0.22 in group 4 (P<0.05; Fig. 5). The total IgE level was 
2.12±0.19 in group 2, but the difference between groups 2 and 4 
was not statistically significant. Mean OVA-specific IgE levels 
were 1.04±0.07 in group 1, 1.23±0.07 in group 2 and 1.28±0.12 in 
group 4; however, the differences were not statistically signifi-
cant between groups 1 and 4 and groups 2 and 4 (Fig. 5). Serum 
total IgE levels were significantly lower only in the comparison 
of groups 1 and 4. In addition, OVA-specific IgE levels tended to 
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Fig. 2.  The effects of oral administration of Lactobacillus rhamnosus (Lcr35) on 
airway hyperresponsiveness. Lactobacillus rhamnosus (Lcr35) administration 
starting 7-day before first OVA sensitization significantly inhibits OVA-induced 
airway hyperresponsiveness to MeCh challenge compared with that of positive 
control group. Data are expressed as the averages of seven mice per group. Val-
ues are expressed as mean±SEM. *P<0.05 and **P<0.01, as compared with 
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Fig. 3.  Total cell counts in BAL fluid. Oral administration of Lactobacillus rham-
nosus (Lcr35) starting 7-day before first OVA sensitization significantly decreas-
es total cell counts in BAL fluid compared with that of positive control group. 
*P<0.05 and **P<0.01, as compared with positive control group (OVA/OVA). 
Data are expressed as the averages of seven mice per group. Values are ex-
pressed as mean±SEM.Yu et al.
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Serum levels of OVA-specific IgG1 and IgG2a
Mean serum levels of OVA-specific IgG1 (A450nm) were 1.42± 
0.11 in group 1, 1.36±0.12 in group 2, and 1.55±0.08 in group 4; 
however, the differences were not statistically significant (Fig. 
5). The OVA-specific IgG1 level was 1.06±0.05 in group 3. Mean 
serum levels of OVA-specific IgG2a (A450nm) were 1.29±0.12 in 
group 1, 1.49±0.05 in group, 2, 0.79±0.3 in group 3 and 1.58±0.09 
in group 4. The differences were not statistically significant be-
tween groups 1 and 4 and groups 2 and 4 (Fig. 5).
Histologic examination of murine lung tissue
Upon hematoxylin-eosin staining, peribronchial and perivas-
cular infiltration of eosinophils was significantly heavier in 
group 1 compared with group 4 (Fig. 6D). However, there was 
no significant difference in eosinophil infiltration between 
groups 2 and 4. Inflammatory changes such as eosinophil infil-
tration were not observed in group 3 (Fig. 6B).
DISCUSSION
The aim of this study was to use a murine model to investigate 
the effects of L. rhamnosus on the prevention of asthma. Airway 















































Fig. 4.  Differential cell count in BAL fluid. 24 hour after the last OVA challenge 
mice were sacrificed and tracheas cannulated for BAL. Cells from BALF were 
counted, spun onto glass slides and stained with Diff-Quik before microscopy. 
*P<0.05 and **P<0.01. Data are expressed as the averages of seven mice per 
group. Values are expressed as mean±SEM.
OVA/OVA + Lcr35 (day -7)











































































































































Fig. 5.  Levels of total IgE, OVA-specific IgE, OVA-specific IgG1 and OVA-specific IgG2a as determined by ELISA in sera of each group. *P<0.05 and **P<0.01. Data are 
expressed as the averages of seven mice per group. Values are expressed as mean±SEM.
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line (maximum concentration) in groups 1 and 2, but the dif-
ference was statistically significant only between groups 1 and 
4. The total number of cells in BAL fluid was significantly less in 
group 1 compared with group 4, and the percentage of eosino-
phils was significantly lower in group 1 compared with group 4. 
Hematoxylin-eosin staining revealed that peribronchial and 
perivascular infiltration of inflammatory cells was significantly 
decreased by treatment with Lactobacillus casei rhamnosus 
Lcr35. These results are consistent with previous studies that 
demonstrated that probiotics decrease airway hyperrespon-
siveness, the number of inflammatory cells in BAL fluid, and 
inflammatory cell infiltration to lung tissue in murine models 
of asthma.
20,21 Airway hyperresponsiveness, the total number of 
cells and the percentage of inflammatory cells in BAL fluid, and 
the degree of inflammatory cell infiltration were not significant-
ly different between groups 2 and 4. This result indicates that 
Lactobacillus casei rhamnosus Lcr35 may have an overt effect 
on the prevention of asthma before rather than after OVA sensi-
tization.
In this study, serum IgE levels were significantly lower in group 
1 compared with group 4 and serum OVA-specific IgE levels 
tended to decrease without any statistical significance. Howev-
er, the serum levels of IgE and OVA-specific IgE were not signif-
icantly different between groups 2 and 4. Given these results, 
we believe that systemic Th2 immune reactions are modified 
by treatment with Lactobacillus casei rhamnosus Lcr35 before 
OVA sensitization, whereas antigen-specific immune reactions 
are not. This is consistent with the result reported by Kalliomaki 
et al.
17 that probiotics administration prevents atopic dermatitis 
but does not decrease sensitization rates in humans. Meanwhile, 
serum levels of OVA-specific IgG1 and IgG2a tended to decrease 
in group 1 without any statistical significance, suggesting that 
Lactobacillus casei rhamnosus Lcr35 may modify immune re-
actions by both Th1 and Th2 cells rather than by either alone. 
Further studies are needed to confirm our results. The mecha-
nism by which probiotics such as Lactobacillus casei rhamno-
sus Lcr35 modulate allergic diseases may not be via restoration 
of the Th1/Th2 imbalance but instead by immunologic tolerance 
induced by the activation of regulatory T cells.
23-26
Many studies have used various strains of probiotics in mu-
rine models of asthma. Similar to our results, Feleszko et al.
20 
demonstrated that both Bifidobacterium lactis Bb-12 and Lac-
A B
C D
Fig. 6.  Effects of Lactobacillus rhamnosus (Lcr35) treatment on pulmonary inflammation. Representative lung sections from 2-group of Lactobacillus rhamnosus 
(Lcr35)-treated mice (A: Lcr35 (day -7), B: Lcr35 (day +12)), negative control mice (C: Saline/Saline) and positive control mice (D: OVA/OVA). The data shown are from 
one representative experiment. Similar results were obtained in three separate experiments using seven mice per group. H&E stain, original magnification: ×100.Yu et al.
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tobacillus rhamnosus GG decrease airway hyperresponsive-
ness, the total number of cells, and the percentage of inflam-
matory cells in BAL fluid. Also consistent with our results, Fe-
leszko et al.
20 showed that serum total IgE levels were decreased 
by the two bacteria. They also reported that the two bacteria 
significantly decrease serum levels of OVA-specific IgE/IgG1 
and prevent asthma before and after OVA sensitization, which 
is not in accordance with our results. This discrepancy may be 
explained by differences in initial time points and total dura-
tion of probiotics administration. Previous studies used mice 
aged 1 day and 8 weeks of probiotics administration, whereas 
our study used mice aged 6 weeks and 3 weeks of probiotics ad-
ministration. Another explanation for the discrepancy may be 
the difference in methods of inducing asthma. Forsythe et al.
21 
suggested that asthma can be prevented by L. reuteri but not by 
L. salivarius. This implies that specific probiotic species are ef-
fective in the prevention and treatment of allergic diseases such 
as asthma. In our study, we found that Lactobacillus casei rham-
nosus Lcr35 prevented asthma. Plausible reasons for this differ-
ence may involve (1) the kinds of probiotics used in murine 
models of asthma, (2) whether the study used live or dead bac-
teria, (3) the initial time point and total duration of probiotics 
administration, (4) the concentration of probiotics used, and (5) 
the method for establishing a murine model of asthma.
In this study, the mice were sensitized twice with OVA. Vari-
ous pathophysiologic parameters were modified in group 1 but 
not in group 2, which suggests that changes in intestinal flora 
during early stages or before OVA sensitization may alter innate 
immunity, subsequently influencing acquired immunity. Fur-
thermore, alterations in systemic immune reactions may pre-
vent asthma.
27
Some clinical studies on probiotics in allergic diseases have 
recently been reported. Rosenfeldt et al.
28 demonstrated that 
administration of L. rhamnosus and L. reuteri improves clinical 
symptoms in patients with atopic dermatitis. A large cohort 
study of Lactobacillus GG administration for 4 weeks revealed 
decreased SCORAD in pediatric patients with atopic dermati-
tis.
29 Other reports, however, have reported little or no therapeu-
tic effects of probiotics on allergic diseases.
30-33 This discrepancy 
may be attributable to the difference in the initial time point of 
probiotics administration. Quite a few studies on the clinical ef-
fects of probiotics in asthma have reported that probiotics have 
no beneficial effect on asthma.
34-37 Some investigations using 
murine models of asthma have reported beneficial effects of 
probiotics.
20,21 The immunomodulatory mechanisms of probi-
otics deserve further investigation.
In conclusion, the results of this study suggest that oral treat-
ment with Lactobacillus casei rhamnosus Lcr35 before sensiti-
zation can attenuate airway inflammation and hyperrespon-
siveness in a murine model of asthma. In addition, Lactobacil-
lus casei rhamnosus Lcr35 may have the potential to prevent 
asthma.
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